ClinicalTrials.gg

Program

FRSW107

A development code.

Its studies are mostly in Hemophilia A, led by 2 companies.

Furthest: phase 3, since Jun 15, 20264 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou Gensciences Biopharmaceutical22 open or runningphase 3since Jun 15, 2026Jun 15, 2026Feb 2027phase 3 · NCT07663903
Jiangsu Gensciences lnc.21 open or runningphase 3since Oct 26, 2023Feb 11, 2022Dec 31, 2026phase 3 · NCT06136507

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2022First study: phase 1 study in Hemophilia ANew to Jiangsu Gensciences lnc.Jiangsu Gensciences lnc. · NCT05251090 · 13 enrolled · China
  2. Oct 26, 2023Phase 3 study in Hemophilia AJiangsu Gensciences lnc. · NCT06136507 · 76 planned · China
  3. Jun 15, 2026Hangzhou Gensciences Biopharmaceutical's first studies: 2 phase 3 studies in Hemophilia ANew to Hangzhou Gensciences BiopharmaceuticalHangzhou Gensciences Biopharmaceutical · NCT07663903, NCT07684898

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Hemophilia AJiangsu Gensciences lnc. · NCT06136507
  2. Feb 2027Primary completion: phase 3 study in Hemophilia AHangzhou Gensciences Biopharmaceutical · NCT07663903
  3. Mar 9, 2027Primary completion: phase 3 study in Hemophilia AHangzhou Gensciences Biopharmaceutical · NCT07684898

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07684898Hemophilia A · China3Active, not recruitingHangzhou Gensciences BiopharmaceuticalMar 9, 202760
NCT07663903Hemophilia A · China3Active, not recruitingHangzhou Gensciences BiopharmaceuticalFeb 202760
NCT06136507Hemophilia A · China3Not yet recruitingJiangsu Gensciences lnc.Dec 31, 202676
NCT05251090Hemophilia A · China1CompletedJiangsu Gensciences lnc.Nov 15, 202113

How it is read

Names in the registry

  • “FRSW107”, 4 entries

Codes read as this program: FRSW107.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.